ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
SANTA CLARA, Calif., Oct. 10, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO™ model in a European based laboratory. The establishment of this improved translational model provides the European scientific community with unfettered access to an advanced research tool for use in preclinical studies of obesity, dysmetabolism and type 2 diabetes.
The FATZO™ is a next generation preclinical research model for obesity, metabolic disorders, diabetes and related complications. The unique feature of an intact leptin system enables the FATZO model to provide novel scientific insights into the physiological and cellular mechanisms that lead from obesity / metabolic disorders to diabetes. It examines polygenic causes of obesity and mimics human pathophysiology by exhibiting metabolic patterns of hyperglycemia and hyperinsulinemia.
“Obesity and diabetes have a significant global impact, affecting more than 422 million people worldwide. We expanded our FATZO™ model to ensure European researchers have ready access to the best translational tools available to advance the drug development programs aimed at curing these diseases,” said Jim Wang, M.D., Crown Bioscience’s Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research.
“The establishment of our FATZO™ model in Europe is pivotal to Crown Bioscience’s commitment to providing translational models that are representative of human conditions of obesity, type 2 diabetes and related comorbidities,” said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. “We look forward to working with European scientists to help answer their most challenging questions about these diseases and enable more effective drug discovery for their treatment.”
For more information on CrownBio’s commitment to advance the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
